Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study  by Schnitzer, T.J. et al.
Osteoarthritis and Cartilage 18 (2010) 629e639Efﬁcacy and safety of naproxcinod in the treatment of patients with osteoarthritis
of the knee: a 13-week prospective, randomized, multicenter study
T.J. Schnitzer y*, A. Kivitz z, H. Frayssinet x, B. Duquesroix x
yNorthwestern University Feinberg School of Medicine, Chicago, IL, USA
zAltoona Center for Clinical Research, Duncansville, PA, USA
xNicOx SA, Sophia-Antipolis, Francea r t i c l e i n f o
Article history:
Received 7 August 2009
Accepted 21 December 2009
Keywords:
Cyclooxygenase-inhibiting nitric-oxide
donator (CINOD)
Naproxcinod
Naproxen
Non-steroidal anti-inﬂammatory drug
(NSAIDs)
Osteoarthritis* Address correspondence and reprint requests to:
western University Feinberg School of Medicine, 710 N
1020, Chicago, IL 60611, USA. Tel: 1-312-503-2315; Fa
E-mail address: tjs@northwestern.edu (T.J. Schnitz
1063-4584/$ e see front matter  2010 Osteoarthriti
doi:10.1016/j.joca.2009.12.013s u m m a r y
Objective: To evaluate the efﬁcacy and safety of the cyclooxygenase-inhibiting nitric-oxide donator,
naproxcinod, compared with naproxen and placebo in patients with osteoarthritis (OA) of the knee.
Method: 918 eligible patients were randomly assigned to double-blind treatment with either naproxci-
nod 375 mg, naproxcinod 750 mg, naproxen 500 mg or placebo, twice daily for 13 weeks. The primary
objective was to show superiority of naproxcinod compared to placebo. Main efﬁcacy criteria were
assessment of pain and physical function using the Western Ontario and MacMaster Universities
Osteoarthritis Index (WOMAC) and patients' overall rating of disease status (Likert scale). The main
secondary objectives were to show that naproxcinod was non-inferior to naproxen 500 mg and to
evaluate overall safety.
Results: Both doses of naproxcinod were statistically and clinically superior to placebo in relieving signs
and symptoms of OA of the knee after 13 weeks of treatment, as demonstrated by all three co-primary
endpoints (P 0.0003). The evaluation of the other secondary efﬁcacy measures was consistent with the
primary endpoint results. Naproxcinod 750 mg was non-inferior to equimolar doses of naproxen 500 mg
in the Intent-to-Treat (ITT) population. 24.5% of patients discontinued prematurely, with a higher
incidence in the placebo group (18.6%) than the active groups (4.3e7.1%) discontinuing due to lack of
efﬁcacy. Both doses of naproxcinod were well-tolerated, with most adverse events being mild or
moderate. Compared to placebo, naproxcinod 750 mg and 375 mg showed a similar blood pressure (BP)
proﬁle in contrast to naproxen which increased BP.
Conclusions: These results demonstrated the clinical efﬁcacy and safety of naproxcinod in the manage-
ment of the signs and symptoms of OA. Naproxcinod was well-tolerated, with BP effects similar to
placebo and different from naproxen.
Clinical Trials.gov identiﬁer: NCT00542555.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a common debilitating, degenerative joint
disease associated with pain, swelling and loss of motion1. OA is
a frequent cause of physical disability amongst adults and has
signiﬁcant socioeconomic impacts2e5. Given the anticipated
increase in the number of OA patients, there is a need for better
tolerated, more effective treatments.Thomas J. Schnitzer, North-
orth Lake Shore Drive, Room
x: 1-312-503-1505.
er).
s Research Society International. PNon-steroidal anti-inﬂammatory drugs (NSAIDs) are commonly
used to manage inﬂammation and pain, the majority of NSAID
prescriptions being for OA and other musculo-skeletal conditions2.
Cyclooxygenase (COX) enzyme inhibition is the basis for NSAID
efﬁcacy, however it also causes adverse effects, in particular blood
pressure (BP) elevation, and increased risk of adverse gastrointes-
tinal (GI) effects, which are associated with increased morbidity
and mortality6e8. Reduced prostaglandin (PG) synthesis as
a consequence of treatment with both selective and non-selective
COX inhibitors may impair the systemic and renal vasodilatatory
beneﬁts of prostacyclin, leading to increases in systemic vascular
resistance, sodium retention and mean arterial BP9e15, as well as
reduced gastric blood ﬂow and mucus production, thereby
increasing the risk of ulcer formation.ublished by Elsevier Ltd. All rights reserved.
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Fig. 1. Patient disposition (ITT population). Note: violation of eligibility criteria includes patients who were found not to meet the study inclusion/exclusion criteria.
Table I
Baseline characteristics (ITT population)
Naproxcinod 750 mg bid
(N¼ 230) n (%)
Naproxcinod 375 mg bid
(N¼ 240) n (%)
Naproxen 500 mg bid
(N¼ 227) n (%)
Placebo
(N¼ 221) n (%)
Age (years), N 230 240 226 221
Mean (SD) 61.6 (9.38) 61.9 (9.21) 61.1 (9.35) 61.0 (9.02)
<65 years, n (%) 150 (65.2) 158 (65.8) 156 (68.7) 150 (67.9)
65 years, n (%) 80 (34.8) 82 (34.2) 70 (30.8) 71 (32.1)
Gender
Male, n (%) 76 (33.0) 63 (26.3) 73 (32.2) 62 (28.1)
Female, n (%) 154 (67.0) 177 (73.8) 153 (67.4) 159 (71.9)
BMI (kg/m2), N 230 240 226 220
Mean (SD) 32.8 (7.67) 33.6 (7.89) 33.0 (7.25) 33.5 (7.59)
ACR classiﬁcation for global functional status
Class I, n (%) 44 (19.1) 48 (20.0) 44 (19.4) 44 (19.9)
Class II, n (%) 130 (56.5) 134 (55.8) 126 (55.5) 121 (54.8)
Class III, n (%) 56 (24.3) 58 (24.2) 56 (24.7) 56 (25.3)
Aspirin use (low dose)*
Yes, n (%) 56 (24.3) 58 (24.2) 51 (22.5) 47 (21.3)
No, n (%) 174 (75.7) 182 (75.8) 176 (77.5) 174 (78.7)
Diabeticy
Yes, n (%) 31 (13.5) 32 (13.3) 22 (9.7) 34 (15.4)
No, n (%) 199 (86.5) 208 (86.7) 205 (90.3) 187 (84.6)
Hypertensivez
Yes, n (%) 118 (51.3) 118 (49.2) 109 (48.0) 113 (51.1)
No, n (%) 112 (48.7) 122 (50.8) 118 (52.0) 108 (48.9)
Womac categoryx
Low, n (%) 20 (8.7) 21 (8.8) 25 (11.0) 24 (10.9)
High, n (%) 210 (91.3) 219 (91.3) 201 (88.5) 197 (89.1)
There were no statistically signiﬁcant differences between the groups for any of the baseline characteristics.
ACR classiﬁcation: Class I e completely able to perform usual activities of daily living (self-care, vocational, and avocational); Class II e able to perform usual self-care
and vocational activities, but limited in avocational activities; Class III - able to perform usual self-care activities, but limited in vocational and avocational activities; Class
IV e limited in ability to perform usual self-care, vocational, and avocational activities.
* Patients on low dose aspirin were deﬁned as those being on 325 mg daily aspirin (preferred term ‘acetylsalicylic acid’) at baseline and throughout the study.
y Diabetic patients were deﬁned according to the patient's medical history at screening.
z Hypertensive patients were deﬁned as those having medical history preferred terms of hypertension present at screening.
x Low WOMAC pain score at baseline was deﬁned as a score< 60 mm, and high WOMAC pain score was deﬁned as a score 60 mm.
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oxygenase-inhibiting nitric-oxide (NO) donator (CINOD) with
analgesic, anti-inﬂammatory, antipyretic and NO-donating
properties. It is rapidly cleaved upon absorption to naproxen and an
NO-donating moiety (data on ﬁle). Naproxcinod has been devel-
oped to provide similar efﬁcacy to non-selective and selective
NSAIDs, while providing an improved safety proﬁle based on the
release of NO which is known to have favourable effects on the
cardiovascular (CV) system and protective GI effects16,17. NO also
inhibits vascular smooth muscle proliferation and regulates inter-
actions between leukocytes and the blood vessel wall which
establish NO as a homeostatic regulator in the vasculature, the
absence of which plays a role in a number of conditions and
pathological states, such as hypertension and vasospasm18,19.
In pre-clinical pharmacodynamic studies, naproxcinod dose-
dependently reduced inﬂammatory pain, inﬂammatory edema,
pyrogen-induced fever and blood COX activity in a manner char-
acteristic of NSAIDs20,21, data on ﬁle. Subsequent short-term dose-
ranging clinical trials in OA demonstrated naproxcinod to have the
potential for good clinical analgesic efﬁcacy, with 750 mg bid
providing maximum clinical efﬁcacy and 375 mg bid being the
lowest effective therapeutic dose22,23. These studies alsoTable II
Baseline and mean change from baseline in WOMAC pain subscale, WOMAC funct
population using modiﬁed LOCF (baseline may be carried forward)
Naproxcinod 750 mg bid
(N¼ 230)
Na
(N
WOMACTM pain subscale score (mm)y
Baseline
N 229 24
Mean (SD) 73.16 (14.930) 73
Change from baseline at Week 13
N 229 24
Mean (Std Dev) 35.29 (27.847) 3
LS Mean (SE) 34.97 (1.755) 3
95% CI* (38.41, 31.52) (
P-value for treatment effect vs placebo* <0.0001 <0
WOMAC function subscale score (mm)y
Baseline
N 229 23
Mean (Std Dev) 71.58 (16.439) 73
Change from baseline at Week 13
N 229 23
Mean (Std Dev) 31.05 (27.319) 3
LS Mean (SE) 31.04 (1.740) 2
95% CI* (34.46, 27.63) (
P-value for treatment effect vs placebo* <0.0001 0.
Patient's overall rating of disease statusz
Baseline
N 229 24
Mean (Std Dev) 1.36 (0.891) 1.
Change from baseline at Week 13
N 229 24
Mean (Std Dev) 1.25 (1.182) 1.
LS Mean (SE) 1.23 (0.070) 1.
95% CI* (1.10, 1.37) (1
P-value for treatment effect vs placebo* <0.0001 <0
* P-values and 95% CI are from pairwise contrasts from ANCOVA model with baseline
y A negative change represents an improvement. A positive change represents a worsen
using the LOCFmethod from the previous visit, unless data were missing due to treatment
have been used if necessary.
z A positive change represents an improvement. A negative change represents a worsen
using the LOCFmethod from the previous visit, unless data were missing due to treatment
have been used if necessary.demonstrated that naproxcinod at clinically effective doses was
associated with a small decrease in supine systolic blood pressure
(SBP) after 4e6 weeks of treatment, whereas SBP tended to
increase in the NSAID comparator groups (naproxen and rofecoxib).
The current double-blind, randomized, multicenter, parallel-
group, naproxen- and placebo-controlled study aimed to support
these ﬁndings over a longer treatment period (13 weeks), and to
provide more information regarding the safety of naproxcinod.
The primary objective of this study was to show that nap-
roxcinod was superior to placebo in relieving OA signs and symp-
toms in patients with OA of the knee after 13 weeks of treatment.
Secondary objectives were to show that naproxcinod was non-
inferior in efﬁcacy to naproxen and to evaluate the general safety,
effects on BP and overall tolerability of the treatments.
Method
The study was conducted in compliance with ICH Good Clinical
Practice and the Declaration of Helsinki, and its applicable
amendments. It was also approved by the appropriate institutional
review boards (IRBs) and patients provided written informed
consent prior to participation in any study-speciﬁc procedures.ion subscale and patient's overall rating of disease status at Week 13 for the ITT
proxcinod 375 mg bid
¼ 240)
Naproxen 500 mg bid
(N¼ 227)
Placebo bid
(N¼ 221)
0 226 221
.58 (15.380) 71.01 (17.177) 72.15 (15.831)
0 226 221
4.62 (27.910) 36.51 (27.194) 24.08 (27.402)
4.10 (1.715) 37.21 (1.768) 24.24 (1.786)
37.47, 30.74) (40.68, 33.74) (27.75, 20.74)
.0001 <0.0001 e
9 226 221
.06 (15.672) 71.05 (17.448) 70.39 (17.760)
9 226 221
0.19 (27.966) 34.07 (27.159) 20.00 (27.182)
9.50 (1.705) 34.30 (1.752) 20.53 (1.773)
32.84, 26.15) (37.74, 30.86) (24.01, 17.05)
0003 <0.0001 e
0 225 221
41 (0.911) 1.36 (0.851) 1.38 (0.787)
0 225 221
14 (1.361) 1.40 (1.369) 0.72 (1.222)
16 (0.068) 1.39 (0.071) 0.72 (0.071)
.03, 1.30) (1.25, 1.52) (0.58, 0.86)
.0001 <0.0001 e
as covariate and treatment as a factor.
ing. Difference is calculated as (ﬁrst group second group). Missing values imputed
-related AE drop out, in which case worst observation was used. Baseline values may
ing. Difference is calculated as (ﬁrst group second group). Missing values imputed
-related AE drop out, in which case worst observation was used. Baseline values may
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September 2006 (last patient visit) at 109 US centers. Males and
females aged 40 years with primary OA of the knee, as conﬁrmed
by radiographs and the American College of Rheumatology (ACR)
guidelines having global functional status I, II or III, were recruited.
Patients were required to be current chronic users of NSAIDs or
acetaminophen for OA pain (i.e., had used NSAIDs or acetamino-
phen at full therapeutic doses for at least 20 days out of 30 days
during the last month prior to the screening visit) and were to have
experienced a ﬂare of pain after a discontinuation period of 5 half
lives of a prior analgesic or anti-inﬂammatory therapy. Patients
were excluded if they had uncontrolled hypertension or uncon-
trolled diabetes (as judged by the investigator), hepatic dysfunction
or renal impairment at screening, recent coronary heart disease or
stroke history within the preceding year, gastroduodenal bleeding
or ulceration history within the prior 6 months, medical or arthritic
disease that could interfere with efﬁcacy evaluations, acute liga-
mentous or meniscal injury of the study joint within 2 years,
arthroscopy of the study joint within 6 months, or if they were
candidates for imminent joint replacement surgery (within 3
months).
Eligible patients were sequentially randomized in a 1:1:1:1 ratio
using a remote system to receive one of four treatments: nap-
roxcinod 750 mg twice daily (bid) (equimolar to naproxen 500 mg
bid and with similar PK proﬁle24), naproxcinod 375 mg bid, nap-
roxen 500 mg bid or placebo bid. Rescue analgesia (acetaminophen
500 mg tablets) was provided for use in case of increased OA pain,
with a maximum accepted dose of 2000 mg/day.
Efﬁcacy was assessed at baseline and Weeks 2, 6, and 13 using
the Western Ontario and MacMaster Universities Osteoarthritis
Index (WOMAC) Visual Analogue Scale (VAS) for pain, stiffness,
and physical function; Modiﬁed Osteoarthritis Research Society
International (OARSI) responder rate (derived from WOMAC
scores); VAS of pain intensity at rest and during walking; patients'
and investigators' overall rating of disease status, treatment and
response to therapy (Likert scale); and Quality of Life Short Form 36Fig. 2. LS Mean and 95% CI change from baseline to Weeks 2, 6 and 13 in WOMAC pain s
population) using LOCF (without baseline carried forward). P-value and 95% CI are from pairw
a factor. P< 0.0001 for all comparisons of naproxcinod 750 mg vs placebo; P 0.0004 for aHealth Survey Questionnaire (SF-36). Additional efﬁcacy
measures included rescue medication use and cumulative rate of
discontinuation for lack of efﬁcacy or worsening of disease.
Safety was assessed by adverse events (AEs), BP measure-
ments, heart rate (HR), laboratory parameters (i.e., hematology,
blood chemistry and urinalysis), body mass index (BMI), and
electrocardiogram (ECG) measurements. BP was measured in
a rigorously standardized manner at each visit, pre-dose at
baseline and 2e4 h post-morning dose of study medication and
other morning medications, including anti-hypertensive treat-
ments, at Weeks 2, 6, and 13. A total of three measurements
were made by a blinded assessor using standard American Heart
Association and 7th report of the Joint National Committee on
Prevention, Detection, Evaluation and Treatment of High Blood
Pressure (JNC-7)25,26 criteria in the sitting position using a cuff
appropriate to arm size (i.e., width of 12 cm for subjects of
normal stature and 15 cm for larger subjects). The examiner was
to ensure that the air in the cuff was emptied between
measurements.
All AEs were recorded and targeted serious AEs (SAEs) were
evaluated by two independent adjudication committees (CV and
GI). Compliance of study medication use was determined by pill
counts and medication history was obtained at each visit.
Statistical methods
The primary efﬁcacy analysis was based on the Intent-to-Treat
(ITT) population (with last observation carried forward [LOCF];
baseline values were not carried forward), which included all
randomized patients and was performed on an as-randomized
basis. Sensitivity analyses were performed on the per-protocol
(PP) population on an as-treated basis (the PP population
included all randomized patients who had no major protocol
deviations during the study). A post-hoc sensitivity analysis using
modiﬁed LOCF method (with baseline carried forward) was also
performed on the ITT population.ubscale, WOMAC function subscale and patient's overall rating of disease status (ITT
ise contrasts from an ANCOVA model with baseline as covariate and with treatment as
ll comparisons of naproxcinod 375 mg vs placebo.
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comparisons of both doses of naproxcinod vs placebo (superiority
contrast) and vs naproxen (non-inferiority contrast) at 13 weeks.
A total of 164 patients per treatment group were needed to reach
95% power to detect a difference of 8 mm (standard deviation
[SD]¼ 20 mm) between each naproxcinod dose and naproxen in
each of the two WOMAC variables. The same number of patients
was needed to detect a difference of 0.4 (SD¼ 1) in patients'
overall rating of disease status. These calculations were based on
a one-sided two-sample t test with an alpha level of 0.025.
Assuming a drop out rate of about 20% over the course of the trial,
a total of 205 patients were needed in each treatment group. The
overall power to detect a statistically signiﬁcant difference for all
three comparisons of the primary endpoint was at least 86% (or
95% cubed). For the superiority tests, the overall power with 205
patients per group was above 97% for all three primary compar-
isons together. These calculations were based on a two-sided two-Table III
Secondary efﬁcacy measures (ITT population)
Naproxcinod 750 mg bid
(N¼ 230)
Napr
(N¼
WOMAC composite pain, stiffness, and function subscale score (mm): change from basel
N 188 198
LS Mean (SE) 36.81 (1.795) 35
Comparisons vs placebo: P-value 0.0013 0.00
VAS pain intensity (mm) at rest: change from baseline at Week 13
N 186 197
LS Mean (SE) 37.84 (1.786) 35
Comparisons vs placebo: P-value 0.0027 0.02
VAS pain intensity (mm) during walking: change from baseline at Week 13
N 186 197
LS Mean (SE) 44.49 (1.904) 41
Comparisons vs placebo: P-value 0.0006 0.01
Patient's overall rating of treatment at Week 13
N 187 202
LS Mean (SE) 2.86 (0.075) 2.84
Comparisons vs placebo: P-value <0.0001 <0.0
Investigator's overall rating of treatment at Week 13
N 187 202
LS Mean (SE) 2.82 (0.074) 2.84
Comparisons vs placebo: P-value <0.0001 <0.0
Investigator's overall rating of disease status at Week 13
N 186 202
LS Mean (SE) 1.38 (0.068) 1.42
Comparisons vs placebo: P-value 0.0034 0.00
Patient's overall rating of the response to therapy at Week 13
N 187 202
LS Mean (SE) 2.77 (0.083) 2.79
Comparisons vs placebo: P-value <0.0001 <0.0
Investigator's overall rating of the response to therapy at Week 13
N 187 202
LS Mean (SE) 2.78 (0.080) 2.78
Comparisons vs placebo: P-value <0.0001 <0.0
Average daily number of rescue medication tablets taken
N 222 232
LS Mean (SE) 1.43 (0.106) 1.33
Comparisons vs placebo: P-value 0.0226 0.00
SF-36 MCS score: change from baseline at Week 13
N 184 195
LS Mean (SE) 2.78 (0.618) 2.92
Comparisons vs placebo: P-value 0.3999 0.31
SF-36 PCS score: change from baseline at Week 13
N 184 195
LS Mean (SE) 8.52 (0.615) 7.08
Comparisons vs placebo: P-value 0.0005 0.04
MCS¼mental component score; PCS¼ physical component score; SE¼ standard error.sample t test with an alpha level of 0.05 and assuming a differ-
ence of 10 mm (SD¼ 20 mm) in the two WOMAC variables and
a difference of 0.5 (SD¼ 1) in patients' overall rating of disease
status.
Analyses were based on an analysis of covariance (ANCOVA),
with treatment group as a factor and baseline as a covariate. For
each analysis, a two-sided test with a signiﬁcance level 0.05 was
used. No adjustment for multiplicity was needed since all three
primary efﬁcacy variables were required to be signiﬁcant based on
a pre-speciﬁed stepwise order. The same ANCOVA model was used
to compare each naproxcinod dose to naproxen 500 mg using both
the ITT and PP populations.
Non-inferiority margins were 8 mm in the WOMAC pain and
function subscales and 0.4 in the patient overall rating of disease
status. For each non-inferiority analysis, the same ANCOVA models
described for the primary efﬁcacy analyses were used. For each
analysis (naproxcinod dose group vs naproxen 500 mg bid), threeoxcinod 375 mg bid
240)
Naproxen 500 mg bid
(N¼ 227)
Placebo bid
(N¼ 221)
ine at Week 13
187 145
.06 (1.75) 39.90 (1.799) 28.03 (2.044)
92 <0.0001 e
189 144
.92 (1.737) 40.51 (1.772) 29.71 (2.032)
05 <0.0001 e
189 144
.82 (1.850) 46.04 (1.890) 34.52 (2.164)
06 <0.0001 e
189 146
(0.072) 2.99 (0.075) 2.34 (0.085)
001 <0.0001 e
189 147
(0.071) 3.00 (0.074) 2.35 (0.083)
001 <0.0001 e
188 147
(0.065) 1.53 (0.067) 1.08 (0.076)
07 <0.0001 e
189 147
(0.079) 2.93 (0.082) 2.26 (0.093)
001 <0.0001 e
189 147
(0.077) 2.95 (0.079) 2.24 (0.090)
001 <0.0001 e
219 210
(0.103) 1.34 (0.106) 1.77 (0.108)
33 0.0042 e
185 142
(0.600) 2.58 (0.616) 1.99 (0.704)
26 0.5288 e
185 142
(0.597) 8.98 (0.613) 5.25 (0.700)
74 <0.0001 e
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three primary variables respectively. If the upper limits of the CIs
for mean change in WOMAC pain and functional subscale scores
and the lower limit of the CI for the overall rating of disease fell
within the corresponding speciﬁc margins, then the non-inferiority
of the given naproxcinod dose against naproxen 500 mg bid was
considered demonstrated.
Safety analyses were based on the safety population, which
included all patients receiving at least one dose of investigational
product, and were performed on an as-treated basis. Patients with
multiple occurrences of an AE were counted only once in the
respective AE category. Patients with multiple AEs within a partic-
ular system organ class or preferred term were counted under the
category of their most drug-related and most severe AE within that
system organ class or preferred term.
Planned BP analyses were based on the standard summary
statistics by treatment group, as well as shift tables showing
baseline and follow-up values. Post-hoc analyses were based on an
ANCOVA with treatment group as a factor and baseline SBP/dia-
stolic blood pressure (DBP) as a covariate. The analyses were per-
formed using two-sided tests at a signiﬁcance level of 5% for both
comparisons vs placebo and comparisons vs naproxen.
Results
A total of 1350 patients were screened and 918were randomized
(Fig. 1). Approximately 70% of patients were female and 30% male
(Table I). Themean agewas 61.4 years (range: 39.6e87.8 years). Two
thirds of patients (66.9%) were aged <65 years and most patients
were white (83.8%). Mean height was 166.7 cm, mean weight was
92.4 kg and mean BMI was 33.2 kg/m2. Baseline characteristics did
not differ signiﬁcantly between groups. Almost half of patients
(49.9%)were considered hypertensive at baseline, 23.1%were taking
low-dosage aspirin (325 mg/day) and 13%were diabetic. A total of
693 patients (75.5%) completed the study and 225 patients (24.5%)
discontinued prematurely (Fig. 1). The most common reasons for
discontinuation were lack of efﬁcacy or worsening of disease, and
AEs. The incidence of premature discontinuation due to lack of
efﬁcacy or worsening of disease was notably higher in the placebo
group (18.6%) compared to the three active treatment groups (4.3%,
7.1%, and 5.3% in the naproxcinod 750 mg, naproxcinod 375 mg and
naproxen groups, respectively [P< 0.001 for all groups]).Table IV
Summary of adverse events by preferred term reported in 2% of patients in any treatm
Preferred term Naproxcinod 750 mg
bid (N¼ 229) n (%)
Na
bid
Any adverse event 108 (47.2) 98
Nausea 8 (3.5) 6
Dyspepsia 12 (5.2) 7
Dizziness 12 (5.2) 3
Constipation 4 (1.7) 5
Headache 2 (0.9) 11
Diarrhea 6 (2.6) 4
Edema peripheral 6 (2.6) 2
Arthralgia 5 (2.2) 8
Injury 1 (0.4) 7
Sinusitis 3 (1.3) 0
Upper respiratory tract infection 2 (0.9) 6
Abdominal pain 5 (2.2) 0
Bronchitis 5 (2.2) 5
Contusion 1 (0.4) 5
Cough 2 (0.9) 2
Rash 5 (2.2) 2
Stomach discomfort 4 (1.7) 1
Urinary tract infection 4 (1.7) 1The primary efﬁcacy parameters were the mean change from
baseline to Week 13 in WOMAC pain and function subscale scores
and the patient's rating of overall disease status. Both doses of nap-
roxcinod were statistically signiﬁcantly superior to placebo for all
three co-primary efﬁcacy endpoints (P 0.0003) (Table II and Fig. 2).
Similar results for each of the primaryefﬁcacyendpointswere seen in
the PP population and ITT population using modiﬁed LOCF (Table II).
Naproxen was statistically superior to placebo for all three co-
primary efﬁcacy endpoints, thus conﬁrming the internal sensitivity
of the study. The results of subgroup analyses by center, age, gender,
race, ethnicity, aspirin use, diabetic status, hypertensive status and
baseline WOMAC pain category were consistent with the results
of the primary efﬁcacy analysis.
In the ITT population at Week 13, both doses of naproxcinod
were statistically non-inferior to naproxen 500 mg regarding the
change from baseline in WOMAC pain subscale score (based on
an upper limit of the 95% CI of 8 mm). In the PP population, nap-
roxcinod 750 mgwas statistically non-inferior to naproxen 500 mg,
with naproxcinod 375 mg failing to show non-inferiority compared
to naproxen 500 mg. For the change from baseline in WOMAC
function subscale score, naproxcinod 750 mg was statistically non-
inferior to naproxen 500 mg, but naproxcinod 375 mg was not. In
the PP population, naproxcinod 750 mg failed to show non-
inferiority. Regarding the change from baseline in the patient's
overall rating of disease status, naproxcinod 750 mg bid was
statistically non-inferior to naproxen 500 mg, but naproxcinod
375 mg failed to achieve statistical non-inferiority to naproxen
500 mg (based on a lower limit of the 95% CI of 0.4). The PP
population showed that both doses of naproxcinod were statisti-
cally non-inferior to naproxen 500 mg.
At Week 13, the modiﬁed OARSI responder rates for the three
active treatments were statistically signiﬁcantly superior to placebo
(P< 0.01). No statistically signiﬁcant difference between naproxen
and either dose of naproxcinod was observed. Signiﬁcantly more
patients discontinued due to lack of efﬁcacy/worsening of the
disease in the placebo group (18.6%) than in the three active
treatment groups (4.3%, 7.1%, and 5.3% for naproxcinod 750 mg,
375 mg and naproxen 500 mg, respectively) (P< 0.001 for each).
There was no statistically signiﬁcant difference between the nap-
roxen and naproxcinod groups. Evaluation of the other secondary
efﬁcacy measures showed consistent results with the primary
efﬁcacy analyses (Table III).ent group (safety population)
proxcinod 375 mg
(N¼ 240) n (%)
Naproxen 500 mg
bid (N¼ 225) n (%)
Placebo bid
(N¼ 222) n (%)
(40.8) 127 (56.4) 86 (38.7)
(2.5) 13 (5.8) 5 (2.3)
(2.9) 9 (4.0) 8 (3.6)
(1.3) 3 (1.3) 6 (2.7)
(2.1) 11 (4.9) 1 (0.5)
(4.6) 6 (2.7) 6 (2.7)
(1.7) 9 (4.0) 5 (2.3)
(0.8) 9 (4.0) 4 (1.8)
(3.3) 3 (1.3) 1 (0.5)
(2.9) 3 (1.3) 2 (0.9)
6 (2.7) 3 (1.4)
(2.5) 5 (2.2) 4 (1.8)
4 (1.8) 0
(2.1) 3 (1.3) 2 (0.9)
(2.1) 5 (2.2) 2 (0.9)
(0.8) 5 (2.2) 3 (1.4)
(0.8) 2 (0.9) 0
(0.4) 5 (2.2) 1 (0.5)
(0.4) 5 (2.2) 2 (0.9)
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days) compared to the active treatment groups (range: 79e82
days). The majority of the patients (90.4%) were compliant,
although compliance was slightly lower in the placebo group.
The incidence of AEs was greater in the naproxen 500 mg group
(56.4%) compared to the naproxcinod 750 mg and 375mg groups
(47.2% and 40.8%, respectively), and was lowest in the placebo group
(38.7%).MostAEsweremildormoderate in severity; theAEs reported
by 2% of patients in any treatment group are shown in Table IV.
The incidence of SAEs was low (naproxcinod 750 mg [1.7%],
naproxcinod 375 mg [0.8%], naproxen [1.3%], and placebo [2.3%])
and the incidence of AEs leading to premature discontinuation was
similar across groups (naproxcinod 750 mg [9.2%], naproxcinod
375 mg [5.8%], naproxen [7.6%], and placebo [6.8%]). The incidence
of treatment-related AEs was similar for naproxen 500 mg (21.3%)
and naproxcinod 750 mg (21.8%), and lower for naproxcinod
375 mg (14.2%) and placebo (16.7%).Table V
Mean baseline and post-dose blood pressure (mmHg), and mean and LS Mean changes f
Study visit
Baseline Week
Systolic blood pressure (mmHg)
Naproxcinod 750 mg bid
N 229 221
Mean (SD) 125.45 (14.125) 123.61
Mean change from baseline (SD) e 1.93
LS Mean change from baseline (95% CI)* 2.03
Naproxcinod 375 mg bid
N 240 235
Mean (SD) 126.51 (13.196) 124.73
Mean change from baseline (SD) e 1.84
LS Mean change from baseline (95% CI)* 1.60
Naproxen 500 mg bid
N 225 220
Mean (SD) 125.59 (14.690) 125.61
Mean change from baseline (SD) e 0.09
LS Mean change from baseline (95% CI)* 0.02
Placebo bid
N 222 213
Mean (SD) 125.97 (12.872) 124.71
Mean change from baseline (SD) e 0.99
LS Mean change from baseline (95% CI)* 1.04
Diastolic blood pressure (mmHg)
Naproxcinod 750 mg bid
N 229 221
Mean (SD) 76.99 (9.077) 74.87
Mean change from baseline (SD) e 2.10
LS Mean change from baseline (95% CI)* 1.97
Naproxcinod 375 mg bid
N 240 235
Mean (SD) 76.62 (8.673) 75.34
Mean change from baseline (SD) e 1.23
LS Mean change from baseline (95% CI)* 1.25
Naproxen 500 mg bid
N 225 220
Mean (SD) 76.61 (8.290) 75.89
Mean change from baseline (SD) e 0.64
LS Mean change from baseline (95% CI)* 0.67
Diastolic blood pressure (mmHg)
Placebo bid
N 222 213
Mean (SD) 76.67 (8.901) 76.16
Mean change from baseline (SD) e 0.29
LS Mean change from baseline (95% CI)* 0.36
* LS Mean changes (95% CI) were obtained from an ANCOVA with treatment as ﬁxed eAt least one GI AE was reported for 17.0% of patients in the
naproxcinod 750 mg group, 12.9% of patients in the naproxcinod
375 mg group, 23.6% of patients in the naproxen group, and 12.2%
of patients in the placebo group. There were four GI SAEs (two GI
hemorrhages in the naproxcinod 750 mg group, one ischemic
colitis in the naproxen group, and one colitis in the placebo
group); all were considered treatment-related. Due to the small
number of events, no meaningful comparisons among groups can
be made.
At least one CV AE was reported for 4.4% of patients in the
naproxcinod 750 mg group, 1.7% of patients in the naproxcinod
375 mg group, 3.1% of patients in the naproxen group, and 2.7% of
patients in the placebo group, with most being related to ECG
changes. There were four CV SAEs (tachycardia and chest pain in
one patient, and myocardial infarction in another patient in the
naproxcinod 750 mg bid group, hypertension in one patient in the
naproxcinod 375 mg bid group, and congestive cardiac failure inrom baseline in blood pressure by study visit (safety population)
2 Week 6 Week 13
204 188
(14.388) 122.02 (14.698) 121.66 (14.554)
(11.637) 3.81 (12.135) 3.74 (12.887)
(3.40, 0.65) 3.92 (5.42, 2.41) 3.92 (5.58, 2.27)
216 202
(13.464) 123.41 (12.629) 123.53 (14.886)
(11.624) 3.52 (12.792) 3.18 (12.238)
(2.93, 0.26) 3.16 (4.63, 1.70) 2.85 (4.45, 1.25)
210 188
(13.527) 124.67 (12.053) 124.74 (13.749)
(11.294) 0.81 (13.144) 0.97 (13.782)
(1.40, 1.36) 1.07 (2.56, 0.41) 1.03 (2.68, 0.62)
181 147
(13.931) 122.71 (14.659) 122.57 (13.701)
(10.918) 3.38 (11.376) 2.94 (11.690)
(2.44, 0.36) 3.38 (4.98, 1.78) 3.07 (4.94, 1.20)
204 188
(9.372) 74.48 (10.048) 74.49 (8.717)
(7.329) 2.72 (7.908) 2.67 (8.156)
(2.89, 1.05) 2.51 (3.52, 1.50) 2.44 (3.50, 1.38)
216 202
(9.290) 74.01 (8.892) 74.41 (9.032)
(7.906) 2.53 (8.559) 2.15 (8.832)
(2.15, 0.36) 2.60 (3.58, 1.62) 2.20 (3.22, 1.18)
210 188
(8.401) 75.50 (8.576) 75.94 (8.049)
(7.906) 1.06 (8.160) 0.58 (8.408)
(1.60, 0.25) 1.12 (2.11, 0.12) 0.65 (1.71, 0.41)
181 147
(8.207) 75.32 (8.060) 75.29 (8.919)
(7.681) 1.17 (8.101) 1.08 (8.449)
(1.30, 0.58) 1.26 (2.33, 0.19) 1.22 (2.42, 0.02)
ffect and baseline SBP/DBP as a covariate.
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ment-related. Two patients (one in the naproxcinod 375 mg group
and one in the naproxen group) had abnormal ECG readings at
study exit that, in the opinion of an independent, blinded cardiol-
ogist, may be due to experiencing a clinically ‘silent’ myocardial
infarction during the study. Based on so few events, no meaningful
comparison among groups can be made.
There were few potentially hypotension-related AEs reported
(pre-deﬁned by the Data Safety Monitoring Board), the most
common of these being dizziness, reported in 5.2% of patients in the
naproxcinod 750 mg group; 1.3% of patients in the naproxcinod
375 mg group; 1.3% of patients in the naproxen group; and 2.7% of
patients in the placebo group.
With respect to BP, small reductions were seen from baseline in
mean SBP following treatment with naproxcinod 750 mg, nap-
roxcinod 375 mg and placebo (Least Square [LS]Mean changes [95%
CI] at Week 13: 3.92 [5.58, 2.27], 2.85 [4.45, 1.25], and
3.07 [4.94, 1.20] mmHg, respectively), whereas in the nap-
roxen group there was no notable change from baseline (LS Mean
changes [95% CI] at Week 13: 1.03 [2.68, 0.62] mmHg). The
difference in LS Mean changes showed that naproxcinod 750 mg
decreased SBP statistically signiﬁcantly more compared with nap-
roxen 500 mg (difference in LS Mean changes [95% CI]: 2.89
[5.23, 0.55]; P¼ 0.0154). Furthermore, there were small reduc-
tions from baseline in mean DBP with naproxcinod 750 mg, nap-
roxcinod 375 mg and placebo (LS Mean changes [95% CI] at Week
13: 2.44 [3.50, 1.38], 2.20 [3.22, 1.18] and 1.22 [2.42,
0.02] mmHg, respectively) comparedwith almost no change from
baseline with naproxen (LS Mean changes [95% CI] at Week 13:
0.65 [1.71, 0.41] mmHg). The difference in LS Mean changes
showed that both naproxcinod 750 mg and 375 mg doses
decreased DBP statistically signiﬁcantly more compared with
naproxen 500 mg (difference in LS Mean changes [95% CI]: 1.79
[3.29, 0.29]; P¼ 0.0193 and 1.55 [3.03, 0.08]; P¼ 0.0386).
The SBP and DBP reductions seen in the naproxcinod groups were
apparent from Week 2 onwards, with the effect then being main-
tained throughout the 13 weeks of treatment (Table V and Fig. 3).vs placebo vs naproxen
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Fig. 3. Difference in LS Mean changes (95% CI) from baseline iOther assessments comprising HR, ECG, BMI, hematology, blood
chemistry, and urinalysis, revealed no safety concerns in any
treatment group.
Discussion
Naproxcinod, a CINOD anti-inﬂammatory drug designed for
treatment of chronic pain, is rapidly cleaved to naproxen and an
NO-donating moiety. Naproxen inhibits both COX-1 and COX-2
enzymes and is an effective anti-inﬂammatory and analgesic
agent. CINODs have been designed to overcome the adverse effects
arising from chronic NSAID administration by exploiting the posi-
tive effect of NO on the GI and CV systems.
Results from this study showed that naproxcinod 375 mgbid and
750 mg bid were statistically superior to placebo in relieving the
signs and symptoms of OA after 13weeks of treatment, as evidenced
by all three co-primary endpoints and secondary efﬁcacy measures.
Beneﬁts were sustained over time and were of a magnitude
accepted as clinically signiﬁcant for pain relief27, with the mean
differences between the groups in theWOMAC pain subscale VAS
ranging from 9 to 12 mm. Similar trends were observed in the sub-
groups of age, gender, race or baseline pain level.
The efﬁcacy of naproxcinod showed dose-dependency, with the
750mg bid dose providing greater improvements at all timepoints
and for all variables. This ﬁnding concurs with results from earlier OA
phase II trials in which efﬁcacy and safety of a range of doses of nap-
roxcinod from 125mg to 1125mg bid were assessed. Naproxcinod
125mg bid failed to show efﬁcacy whereas all doses 375mg bid
were efﬁcacious. Importantly, no additional beneﬁtwas observedwith
doses of naproxcinod at 1125mgbid compared to 750mgbid23. These
efﬁcacy results correspond with recent guidelines for OA manage-
ment, suggesting a stepwise therapeutic approach starting with the
lowest effective dose. The potential for two different doses of nap-
roxcinoddemonstratingclinical efﬁcacyprovidesdosingﬂexibility just
as with naproxen and ibuprofen, the most widely used NSAIDs.
Study limitations include the fact that subjects were only fol-
lowed for 13 weeks of treatment, and efﬁcacy and safety evaluationvs placebo vs naproxen
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n post-dose SBP and DBP at Week 13 (safety population).
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is standard for such trials, but does not mimic the usual clinical
setting, although it does permit better distinction of efﬁcacy, and
the inclusion of a widely used positive control used in treating OA
provides a benchmark. Additionally, although subjects were drawn
from a general OA population, screening criteria excluded certain
sub-groups. Finally, one cannot exclude selective discontinuations
which could have an impact on the results. Strengths of the study
include the completeness of data collection and standardization of
BP measurements.
The choice of NSAID is often dictated by safety considerations,
particularly as patients with OA often have clinically important co-
morbidities. CINODs were speciﬁcally developed to provide the
potential for greater GI and CV safety than seen with existing
NSAIDs. NO is known to have important physiologic and potentially
beneﬁcial pharmacologic actions on both the GI and CV systems;
the challenge has been to develop a means of delivering sustained
NO activity to the target tissues, in contrast with existing organic
nitrates which have both a rapid onset and generate tolerance to
their activity. Non-clinical pharmacology studies with CINODs have
clearly demonstrated an activity attributed to NO in both the GI and
CV systems. Non-clinical studies comparing naproxcinod with
naproxen have shown increased GI blood ﬂow, increased mucus
production, reduced leukocyte adherence and gastroprotection21.
Other investigations have reported marked beneﬁcial effects of
naproxcinod on BP in several different murine models of
hypertension. The results of all these studies were consistent with
a prolonged and sustained NO activity in animal experiments.
The concept of decreased GI-damaging properties of naproxci-
nod in comparisonwith naproxen has been supported by the results
from two 12-day studies on gastric mucosal injury in healthy
volunteers and a 6-week endoscopy trial in subjects with OA24,28,29.
In this study, naproxcinod 750 mg showed a comparable general
safety and tolerability proﬁle to naproxen 500 mg. Naproxcinod
375 mg showed a similar safety and tolerability proﬁle compared
with placebo and appeared to have a better safety and tolerability
proﬁle than naproxcinod 750 mg and naproxen 500 mg. Naproxci-
nod was generally well-tolerated, with only a small number of
potential NO mechanism-based events, particularly dizziness,
reported at the higher dose. Dizziness has also been reported with
other NSAIDs30. No difference between the groups in early discon-
tinuation due to AEs, particularly due to hypotension-related AEs
was noted. Few serious GI or CV AEs were reported, with no major
imbalance among the groups; however, because of the small
number of events, the possibility of a difference cannot be excluded.
Larger and longer trials will need to be undertaken to obtain a more
accurate determination of the GI and CV safety of naproxcinod.
In previously reported phase 2 OA studies22,23,28, subjects treated
with naproxcinod consistently showed a small decrease in BP
compared to subjects treated with placebo, contrasting with
increases in BP observed in subjects treated with naproxen or
rofecoxib. This phase 3 trial comprised a larger group of patients that
is considered representative of the general OA population, and
conﬁrms the earlier ﬁndings of a differential BP response with nap-
roxcinod compared to naproxen. Naproxcinod 750 mg and nap-
roxcinod 375mg showed reductions fromBaseline in SBPatWeeks 2,
6 and 13 that were similar in magnitude to SBP changes seen in the
placebo group. In contrast, naproxen increased SBP compared to
placebo, with the difference in SBP between the naproxcinod 750 mg
group and the naproxen 500 mg group being statistically signiﬁcant.
These results observed with naproxcinod are clinically relevant.
In this study, the efﬁcacy of naproxcinod was clearly demonstrated,
with naproxcinod 750 mg bid being non-inferior to equimolar
doses of naproxen 500 mg bid. The overall safety proﬁle of 750 mg
of naproxcinod was similar to that of 500 mg of naproxen, with the375 mg naproxcinod and placebo groups having fewer safety issues
reported. As naproxen is generally considered one of the safer
NSAIDs from a CV perspective31e33, the BP changes following
treatmentwith naproxcinod compared to naproxenmay provide an
additional factor reducing CV risk.
As approximately 50% of the OA population has concurrent
hypertension, the availability of an agent like naproxcinod that
does not appear to increase BP compared to placebo, unlike other
NSAIDs, has the potential to address an important medical need.
Further studies, including those speciﬁcally focusing on the longer-
term safety of naproxcinod and its effects on BP throughout the day
(e.g., ambulatory BPmonitoring [ABPM]) and over longer periods of
time will guide its future use in OA patients.
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